Close Menu

NEW YORK – Austrian biopharma firm Viravaxx said on Tuesday that it is collaborating with the Medical University of Vienna to create a platform for diagnostic and vaccine research into COVID-19.

The collaborators will use a protein microarray comprising the proteome of SARS-CoV-2 to enable high resolution identification of viral antigens that elicit an immune response. Additionally, they are developing an ELISA that will allow them to investigate whether sera from recovered COVID-19 patients are able to neutralize the virus and to map viral epitopes.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.

The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.

The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.

In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.